Deimmunized lysostaphin and methods of use
Compositions comprising deimmunized lysostaphin and methods of using the same, e.g., to treat microbial infection in or on a subject, are provided.
1. A deimmunized lysostaphin or fragment thereof, comprising a mutation at one or more amino acid positions of Thr127, Ser126, Ser124, Ser122, Asn121, Val120, Met119, Arg118, Ile99, Lys95, Tyr93, Ser84, Leu83, Val75, Asn72, Ile70, Lys46, Ile41, Asn40, Phe38, Tyr33, Asn13, or Asn12 of SEQ ID NO:49,
wherein the fragment comprises a catalytically active domain of a lysostaphin,
wherein the de-immunized lysostaphin or fragment thereof is at least 90% identical to the catalytically active domain of a lysostaphin of SEQ ID NO: 49,
wherein the mutation at Ser124 is Ser124Gly.
2. The deimmunized lysostaphin of claim 1 , wherein said lysostaphin is aglycosylated.
3. The deimmunized lysostaphin of claim 1 , wherein the mutation comprises Thr127Ala; Ser126Pro; Ser124Gly; Ser122Asp, Ser122Gly, or Ser122Thr; Asn121Gly; Val120Asp; Met119Arg; Arg118Thr; Ile99Gln; Lys95Glu; Tyr93His; Ser84Tyr or Ser84Gly; Leu83Met; Val75Glu or Val75Gln; Asn72His; Ile70Lys; Lys46His; Ile41Glu; Asn40Thr; Phe38Ser; Tyr33Thr; Asn13His; Asn12Gly; or a combination thereof.
4. The deimmunized lysostaphin of claim 1 , further comprising one or more amino acid substitutions in the C-terminal binding domain.
5. A pharmaceutical composition comprising the deimmunized lysostaphin of claim 1 and a pharmaceutically acceptable carrier.
6. The pharmaceutical composition of claim 5 , further comprising an antibiotic.
7. The pharmaceutical composition of claim 6 , wherein said antibiotic comprises a β-lactam, cephalosporin, aminoglycoside, sulfonamide, antifolate, macrolide, quinolone, glycopeptide, polypeptide or a combination thereof.
8. A method for preventing or treating a microbial infection comprising administering to a subject in need of treatment the pharmaceutical composition of claim 5 , thereby preventing or treating the subject's microbial infection.
9. The method of claim 8 , wherein said infection is a bacterial infection.
10. The method of claim 9 , wherein said bacterial infection is caused by bacteria from the genus Staphylococcus.
11. The method of claim 8 , wherein the pharmaceutical composition is administered by a route selected from the group consisting of topical, ophthalmic, intranasal, intravenous, intramuscular, subcutaneous, intraperitoneal, intrathecal, and inhalation delivery.
12. The method of claim 8 , wherein the pharmaceutical composition is provided on a medical device.
13. A method for preventing or treating a biofilm comprising administering to a subject in need of treatment the pharmaceutical composition of claim 5 .
14. The aglycosylated lysostaphin of claim 2 , comprising a mutation at Ser126, Thr127, and/or Ser234.
15. The aglycosylated lysostaphin of claim 2 , comprising the mutation Ser126Pro, Thr127Ala, and/or Ser234Lys.
16. The deimmunized lysostaphin of claim 4 , comprising a mutation at one or more of Asn236, Ser234, Asn232, Asn219, Ile200, Val193, Ser191, Arg186, Ala169, Ser168, Ser166, or Tyr160, wherein the mutation at Asn232 is Asn232Gln.
17. The deimmunized lysostaphin of claim 4 , wherein the mutation comprises Asn236Asp, Ser234Lys, Asn232Gln, Asn219Tyr, Ile200Thr, Val193Trp, Ser191Ala Arg186Thr, Ala169Gly, Ser168Lys, Ser166Asn or Ser166Thr, Tyr160His, or a combination thereof.
18. A vector encoding the deimmunized lysostaphin of claim 1 .
19. The pharmaceutical composition of claim 6 , wherein said antibiotic comprises an inhibitor of cell wall synthesis or protein synthesis.
20. A deimmunized lysostaphin or fragment thereof, comprising a mutation at one or more amino acid positions selected from the group consisting of: Asn236, Asn232, Arg186, Ala169, Ser166, Tyr160, Ser126, Ser124, Ser122, Asn121, Ile99, Lys95, Leu83, Ile41, or Asn12 of SEQ ID NO: 49, wherein:
the fragment comprises a catalytically active domain of a lysostaphin or a cell wall binding domain of a lysostaphin; and
the mutation at Asn232 is Asn232Gln and the mutation at Ser124 is Ser124Gly.
21. A de-immunized lysostaphin or fragment thereof where the lysostaphin or fragment thereof comprises a cell wall binding domain of lysostaphin wherein said cell wall binding domain comprises a mutation at one or more amino acid positions of Asn236, Ser234, Asn232, Asn219, Ile200, Val193, Ser191, Arg186, Ala169, Ser168, Ser166, or Tyr160 of SEQ ID NO: 49, wherein the mutation at Asn232 is Asn232Gln.
22. The de-immunized lysostaphin or fragment thereof of claim 21 , wherein the mutation comprises Asn236Asp, Ser234Lys, Asn232Gln, Asn219Tyr, Ile200Thr, Val193Trp, Ser191Ala, Arg186Thr, Ala169Gly, Ser168Lys, Ser166Asn, Tyr160His, or a combination thereof.
23. The deimmunized lysostaphin fragment of claim 20 , wherein the lysostaphin fragment comprises a catalytically active domain of a lysostaphin.
24. The deimmunized lysostaphin fragment of claim 20 , wherein the lysostaphin fragment comprises a cell wall binding domain of a lysostaphin.
25. A vector encoding the deimmunized lysostaphin of claim 21 .
26. A method for preventing or treating a biofilm comprising administering to a subject in need of treatment the pharmaceutical composition of claim 5 , wherein the pharmaceutical composition is co-administered with an antibiotic.
27. The method of claim 26 , wherein the pharmaceutical composition and the antibiotic are co-administered simultaneously or alternating.
28. A method for preventing or treating a microbial infection comprising administering to a subject in need of treatment the pharmaceutical composition of claim 5 , thereby preventing or treating the subject's microbial infection, wherein the pharmaceutical composition is co-administered with an antibiotic.
29. The method of claim 28 , wherein the pharmaceutical composition and the antibiotic are co-administered simultaneously or alternating.
30. A method for producing a deimmunized lysostaphin, comprising:
a) introducing the vector of claim 18 into a cell to produce a deimmunized lysostaphin-expressing cell;
b) culturing the cell in a bioreactor culture system; and
c) isolating the deimmunized lysostaphin from the bioreactor culture system.
31. The method of claim 30 , wherein the cell is a yeast cell.
32. The method of claim 30 , wherein the cell is selected from the group consisting of: Pichia pastoris, E. coli, Bacillus sphaericus , and Lactococcus lactis.
33. A method for producing a deimmunized lysostaphin, comprising:
a) introducing the vector of claim 25 into a cell to produce a deimmunized lysostaphin-expressing cell;
b) culturing the cell in a bioreactor culture system; and
c) isolating the deimmunized lysostaphin from the bioreactor culture system.
34. The method of claim 33 , wherein the cell is a yeast cell.
35. The method of claim 33 , wherein the cell is selected from the group consisting of: Pichia pastoris, E. coli, Bacillus sphaericus , and Lactococcus lactis.